87.82
price down icon0.91%   -0.81
after-market Handel nachbörslich: 87.82
loading
Schlusskurs vom Vortag:
$88.63
Offen:
$87.94
24-Stunden-Volumen:
551.56K
Relative Volume:
0.76
Marktkapitalisierung:
$5.59B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-31.25
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
-1.72%
1M Leistung:
+41.67%
6M Leistung:
+53.45%
1J Leistung:
+76.42%
1-Tages-Spanne:
Value
$87.09
$89.67
1-Wochen-Bereich:
Value
$87.09
$92.14
52-Wochen-Spanne:
Value
$40.61
$94.80

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Firmenname
Rhythm Pharmaceuticals Inc
Name
Telefon
857-264-4280
Name
Adresse
222 BERKELEY STREET, BOSTON, MA
Name
Mitarbeiter
283
Name
Twitter
@rhythmpharma
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
RYTM's Discussions on Twitter

Vergleichen Sie RYTM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
87.82 5.90B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Eingeleitet Goldman Buy
2025-07-07 Eingeleitet Leerink Partners Outperform
2025-04-07 Hochstufung BofA Securities Neutral → Buy
2025-03-05 Fortgesetzt Stifel Buy
2025-01-02 Eingeleitet Jefferies Buy
2024-12-20 Eingeleitet Oppenheimer Outperform
2024-10-21 Eingeleitet Guggenheim Buy
2024-09-18 Eingeleitet H.C. Wainwright Buy
2024-09-17 Eingeleitet JMP Securities Mkt Outperform
2024-05-08 Herabstufung BofA Securities Buy → Neutral
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-08-01 Hochstufung BofA Securities Neutral → Buy
2023-01-18 Fortgesetzt Canaccord Genuity Buy
2022-08-08 Hochstufung Goldman Neutral → Buy
2022-08-05 Hochstufung BofA Securities Underperform → Neutral
2022-06-17 Bestätigt Needham Buy
2022-03-02 Fortgesetzt Stifel Buy
2022-02-17 Hochstufung Ladenburg Thalmann Neutral → Buy
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-14 Fortgesetzt Goldman Neutral
2021-08-04 Herabstufung BofA Securities Neutral → Underperform
2021-08-04 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-11-30 Herabstufung BofA Securities Buy → Neutral
2020-01-08 Eingeleitet Goldman Sell
2019-07-12 Hochstufung Stifel Hold → Buy
2019-07-08 Eingeleitet Canaccord Genuity Buy
2019-03-13 Eingeleitet Ladenburg Thalmann Buy
2018-09-07 Fortgesetzt Morgan Stanley Overweight
2018-06-25 Bestätigt Needham Buy
2018-06-15 Bestätigt Needham Buy
2017-10-30 Eingeleitet BofA/Merrill Buy
2017-10-30 Eingeleitet Needham Buy
Alle ansehen

Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Rhythm Pharmaceuticals Inc. a good long term investmentRapid growth trajectories - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Rhythm Pharmaceuticals Inc. stock priceConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Should You Invest in This Under-the-Radar Weight Loss Stock? - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

Rhythm Pharmaceuticals prices $175M stock offering - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 15, 2025

Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada

Jul 15, 2025
pulisher
Jul 13, 2025

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals announces public offering of common stock - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN

Jul 12, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Guggenheim Raises Rhythm Pharmaceuticals (RYTM) Price Target Ami - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Shares Slide Following Stock Offering - GuruFocus

Jul 10, 2025

Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):